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Increased Expression of NAPDH Oxidase 4 (NOX4) in Systemic 
Sclerosis Dermal Fibroblasts: Regulation by Transforming 
Growth Factor β
Sonsoles Piera-Velazquez, Ph.D., Alma Makul, M.S., and Sergio A. Jimenez, M.D.
Jefferson Institute of Molecular Medicine, The Scleroderma Center, Thomas Jefferson University
Abstract
Objective—Systemic Sclerosis (SSc) is characterized by severe and often progressive skin and 
multiple internal organ fibrosis. The mechanisms responsible for these alterations remain obscure, 
although excessive ROS-mediated oxidative stress has been implicated. NOX4 is one of seven 
NADPH oxidase isoforms responsible for ROS generation. Here, we examined NOX4 expression 
in SSc skin and cultured dermal fibroblasts and its regulation by TGF-β.
Methods—NOX4 was assessed in normal and SSc skin employing immunohistology, and in 
normal and SSc cultured dermal fibroblasts by quantitative PCR, fluorescence microscopy and 
Western blots. ROS levels were assessed by fluorescence measurements of H2O2 production. The 
TGF-β signaling involved in NOX4 stimulation was studied employing specific kinase inhibitors. 
NOX4 inhibition/downregulation was induced with a selective NOX4 small molecule inhibitor 
and NOX4 siRNA.
Results—In contrast with normal skin SSc skin fibroblasts showed intense NOX4 staining. 
Cultured SSc fibroblasts displayed increased NOX4 expression. TGF-β1 caused potent NOX4 
protein and mRNA stimulation in normal and SSc fibroblasts mediated by PKC-δ and SMAD2/3 
pathways. NOX4 knockdown in SSc fibroblasts reduced ROS production and lowered collagen I 
expression.
Conclusion—NOX4 expression and production are constitutively elevated in SSc skin and 
cultured SSc dermal fibroblasts. TGF-β1 stimulates NOX4 expression in normal and SSc 
fibroblasts through PKC-δ and Smad2/3 signaling pathways. A small molecule NOX4 inhibitor 
decreased fibroblast collagen and fibronectin production and NOX4 siRNA knockdown reduced 
SSc fibroblast ROS and collagen production. These results demonstrate NOX4 involvement in 
SSc-associated fibrosis and suggest NOX4 inhibitors as novel therapeutic approaches for SSc.
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INTRODUCTION
The pathogenesis of Systemic Sclerosis (SSc) is complex and despite numerous studies that 
examined diverse aspects of its intricate picture the exact mechanisms involved are not well 
understood [1–4]. However, it is apparent that the most severe clinical and pathologic 
manifestations of the disease are the result of a fibrotic process characterized by the 
excessive and often progressive deposition of collagen and other connective tissue 
macromolecules in skin and numerous internal organs [5–8] and by a severe 
fibroproliferative vasculopathy preferentially affecting the microvasculature [9–11]. The 
mechanisms involved in the initiation and progression of the remarkable fibrotic and 
vasculoproliferative processes in SSc remain largely unknown. Extensive studies have 
shown that Transforming Growth Factor β (TGF-β) plays a crucial role in SSc pathogenesis 
owing to its potent and pleitropic profibrogenic effects [12–14]. Thus, the most promising 
novel therapeutic approaches for SSc and other fibrotic disorders include modifiers of TGF-
β1 activation and signaling and are currently being intensively investigated [15–17]. 
However, owing to the important functions of TGF-β in numerous homeostatic processes a 
therapeutic approach involving global inhibition of its activity may be associated with 
undesirable adverse effects. Thus, there is a strong interest in the identification of 
downstream mediators of TGF-β profibrotic effects for the therapy of SSc and other fibrotic 
disorders with the expectation that their inhibition may lead to potent anti-fibrotic effects 
without the serious side effects that may result from global TGF-β inhibition.
One novel pathway that has been recently recognized as a potentially important participant 
in various fibrotic processes including idiopathic pulmonary fibrosis (IPF) and SSc involves 
reactive oxygen species (ROS). Although ROS are produced by normal fibroblasts and are 
essential for numerous important intracellular reactions, several studies have implicated 
excessive oxidative stress with the generation of deleterious ROS in the pathogenesis of SSc 
and other fibrotic disorders [18–23]. Indeed, numerous studies have provided strong 
evidence for the participation of ROS in the fibrotic process in IPF [24]. However, the role 
of ROS-induced oxidative stress in SSc pathogenesis has not been studied as extensively, 
although, it has been shown that SSc fibroblasts produce elevated ROS levels constitutively 
and it has been suggested that elevated ROS may be involved in the increased collagen 
expression in these cells [18, 21]. The presence of severe oxidative stress and high oxidative 
DNA damage in SSc has been confirmed by the observation of increased urinary 8-oxodG 
levels [20], and other studies have shown elevated ROS levels in monocytes and plasma 
from SSc patients [25–27] providing strong evidence for the important contribution of 
oxidative stress in SSc pathogenesis.
Although there are multiple sources of intracellular ROS, including ROS production by 
mitochondria, extensive studies have shown that most ROS production derives from the 
activation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system 
[28–30]. NOX4 is one of seven NADPH isoforms and like other NADPH isoforms its 
structure consists mainly of a six-transmembrane domain known as the gp91phox domain. 
Despite their extensive similarity in structure and enzymatic function members of the NOX 
family differ in their mechanism of activation. NOX4 lacks potential regulatory subunits, 
therefore, it is generally accepted that NOX4 is constitutively active and the regulation of its 
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effects occurs mainly at the expression level [31]. Thus, the regulation of NOX4 expression 
may play a crucial role in the pathogenesis of ROS-mediated disorders. Although the role of 
NOX4 as an important downstream mediator of TGF-β-induced profibrotic effects has been 
demonstrated [32] and the participation of NOX4 in the pathogenesis of tissue fibrosis in 
various fibrotic disorders such as IPF and liver fibrosis has been the subject of several recent 
studies [33–35], the possible role of NOX4 in the initiation or establishment of the SSc-
associated fibrotic process has not been examined extensively. We describe here studies 
demonstrating increased levels of NOX4 epitopes in fibroblastic cells in the dermis of 
affected SSc skin compared to normal skin samples and the increased expression of NOX4 
transcripts in cultured SSc dermal fibroblasts. Furthermore, we describe studies 
demonstrating a potent stimulation of NOX4 gene expression by TGF-β and examining the 
signaling pathway involved in TGF-β regulation of NOX4 expression. We also report that a 
small molecule selective NOX4 inhibitor causes a dose-related reduction in fibroblast 
collagen and fibronectin production and that siRNA NOX4 knockdown reduces SSc 
fibroblast ROS and type I collagen production.
MATERIALS AND METHODS
Materials
Trypsin and bacterial collagenase were from Worthington Biochemical Corporation 
(Lakewood, NJ). DMEM, L-glutamine, penicillin, streptomycin and vitamins were from 
Corning Cellgro (Manassas, VA). Fungizone was from Life-Technologies (Carlsbad, CA), 
and FBS from Atlanta Biologicals (Lawrenceville, GA; now Thermo Scientific Pierce, 
Rockford, IL). The NOX4 polyclonal antibody was from ABR Affinity BioReagents, 
(Golden, CO) and the collagen type I polyclonal antibody from SouthernBiotech 
(Birmingham, AL). The β-actin monoclonal antibody, TGF-β, and ascorbic acid were from 
Sigma (St. Louis, MO). Rottlerin was from Axxora (San Diego, CA), imatinib from LC 
Laboratories (Woburn, MA), and SB431542 from Cayman Chemicals (Ann Arbor, MI). 
Five- (and 6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA; 
C369) was from Invitrogen, Life Technologies (Thermo Fisher Scientific, Waltham, MA). 
GKT137831(GKT) is a specific dual NOX4/NOX1 inhibitor synthetized by GenKyoTex 
S.A. displaying very high NOX4/NOX1 specificity [36–40]. This compound was made 
available to us through a collaborative study with Dr. Patrick Page from GenKyoTex S.A. 
(Plan-les-Ouates, Switzerland).
Isolation and culture of fibroblasts
Normal dermal fibroblasts were obtained from the volar surface of forearms of healthy 
volunteers following their informed consent. SSc fibroblasts were obtained from skin biopsy 
specimens from the proximal edge of forearm lesions of patients with diffuse SSc of recent 
onset, as described previously [41, 42]. The cells were cultured and maintained at 37°C in a 
5% CO2 humidified atmosphere in DMEM (Corning Cellgro) containing 10% FBS, 2 mM 
L-glutamine, 100 U penicillin, 100 µg/ml streptomycin. Fibroblasts were used for 
experiments between passages 3 and 6.
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Immunohistology of normal and SSc skin
Normal skin was obtained from the dorsal forearm of normal human donors with their 
informed consent following IRB approved protocols. SSc skin was obtained from skin 
biopsies from patients with diffuse cutaneous SSc of recent onset as described previously 
[41, 42] performed at the Scleroderma Center of Thomas Jefferson University for diagnostic 
purposes. The normal and SSc skin tissues were fixed in buffered formalin phosphate and 
subsequent paraffin embedding and sectioning. Sections were examined by 
immunohistology with a polyclonal antibody against NOX4 (R&D Systems, Inc. 
Minneapolis, MN), following the streptavidin-biotin method with AEC as chromogen using 
the Histostain-Plus kit (Invitrogen) according to the manufacturer’s instructions.
Immunofluorescence
Normal and SSc dermal fibroblasts were cultured in plastic chamber slides and cells were 
fixed using 10% buffered formalin phosphate (Fisher, Pittsburg, PA) for 20 min and 
permeabilized with TritonX-100 (Sigma). Cells were incubated with NOX4 antibody (1:100 
dilution) for 18 h and stained with Cy3 secondary antibody (1:50 dilution) for 1 h at 37°C. 
Cells were mounted following nuclear counterstaining with 4,6-diamidino-2-phenylindole 
staining (DAPI) and visualized by fluorescence microscopy. Sections were analyzed using a 
Zeiss LSM 510 META confocal laser scanning microscope system. The breakthrough of the 
DAPI signal into the red or the green channel was recorded separately. Zeiss META 
enhancement software was used in balancing the signal strength, and the image was scanned 
to separate signal from noise. Panels were assembled using Photoshop software without any 
RGB modification.
ROS detection
Normal and SSc human dermal fibroblasts were treated either with TGF-β1 (10 ng/mL) 
alone or with TGF-β1 plus GKT137831 (GKT; 10 µM) for 4–6 h at 37°C. ROS detection 
was performed using fluorescence of H2O2 production employing 5-(and-6)-carboxy-2’,7’-
dichlorodihydrofluorescein diacetate (CM-H2CDCFDA) oxidation [43] according to the 
manufacturer's instructions. Briefly, cells were washed twice with HBSS buffer, incubated 
with 10 µM CM-H2DCFDA for 15 min at 37°C, then washed with PBS three times and 
fixed with 2% paraformaldehyde. Samples were then mounted immediately prior to imaging 
by fluorescence microscopy. Images were obtained following 1 min of exposure to the 
microscope’s light source.
Fluorescence analysis
The intensity of fluorescence of a specific microscopic field was analyzed with ImageJ 
software (NIH, Bethesda, MD), calculating the sum of the intensity of each pixel and was 
expressed as corrected total cell fluorescence (CTCF). The CTCF value measures the overall 
fluorescence intensity in a given microscopic field calculated with the integrated density of 
fluorescence and corrected for the surface area examined and the background. The average 
of the CTCF values was used in statistical analysis using a two-tailed unpaired t-test. P < 
0.05 was considered statistically significant.
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RNA extraction and semi-quantitative PCR
Normal and SSc fibroblasts were grown in culture under control conditions (untreated) or 
were treated with TGF-β1 (10ng/mL), or with TGF-β1 plus either the selective PKC-δ 
inhibitor rottlerin (5 µM), or specific inhibitors of c-Abl (imatinib; 10 µg/mL), and Smad 2/3 
(SB431542; 10 µM), or various concentrations of GKT. Cells were harvested following 24 h 
of treatment and total RNA was extracted using the TRIzol reagent (Invitrogen). RT-PCR 
amplification of target mRNA was performed with 1 µg of RNA to generate first strand 
cDNA by using the SuperScript II reverse transcriptase (Invitrogen). PCR was performed 
using specific primers for NOX4 and β-actin. The primers used for PCR are listed in 
Supplementary Table 1. Quantitative real time PCR was performed utilizing the QuantiTect 
SYBR green PCR kit (Qiagen, Valencia, CA) on an ABI PRISM 7700 real time PCR 
machine. PCR was performed utilizing the cycling conditions of 95°C for 3 min followed by 
40 cycles of 95°C for 30 sec/55°C for 30 sec. The method of relative quantitation {ΔΔCt} 
was employed to determine the level of gene expression in cultured dermal fibroblasts. ΔCt 
values were computed from the Ct (cycle threshold number) values of the human NOX4 
gene and the housekeeping control gene.
Western blots
Human dermal fibroblasts were harvested and lysed in RIPA lysis buffer containing protease 
inhibitors and 30 µg of the extracts were separated by electrophoresis in SDS 
polyacrylamide gels under reducing conditions as described previously [41, 42]. Media from 
cell cultures were collected after 48 h and 15 µL were electrophoresed on 3–12% 
polyacrylamide gradient gels. Separated proteins were electroblotted onto nitrocellulose 
membranes (Invitrogen) and the membranes were blocked in PBS/5% dry milk/0.1% normal 
goat serum for 1 h at room temperature. The transferred proteins were reacted for 18–20 h at 
4°C with NOX4 and β-actin antibodies for cell extracts and collagen type I for medium 
proteins. Appropriate secondary antibodies coupled to peroxidase and the ECL detection 
system (Thermo Scientific Pierce) were employed for detection. Densitometry quantification 
was performed using ImageJ software (NIH) and the signals were normalized to those of β-
actin or total protein loading assessed from coomasie blue staining of the gels.
PKC-δ and NOX4 siRNA transfections
Normal human dermal fibroblasts were cultured as described above and specific PKC-δ 
siRNA transfection was performed using HiPerfect reagent (Qiagen) following the 
manufacturer’s instructions. Briefly, 3×104 cells were cultured until 70–80% confluence and 
were transfected with the transfection reaction prepared in serum free media containing 10 
nM PKC-δ siRNA and 6 µL of Hiperfect reagent preincubated for 10 min at room 
temperature. For NOX4 siRNA transfection SSc human dermal fibroblasts were cultured as 
described above and specific NOX4 siRNA transfection was performed using Lipofectamine 
(Invitrogen) following the manufacturer’s instructions. Briefly, cells were cultured until 
50% confluency and transfected with the transfection reaction prepared in Opti-MEM media 
containing NOX4 siRNA to 33nM final concentration and Lipofectamine preincubated for 
20 min at room temperature. Cells were incubated with this transfection reaction for 12 h. 
All Stars siRNA (Qiagen) was used as control.
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Statistical Analysis
The significance of differences between the control and the experimental groups was 
determined by statistical analysis using ANOVA or Student’s t-test assuming equal 
variances. P-values <0.05 were considered statistically significant. Data are represented as 
either the mean ± SEM or the mean ±SD.
RESULTS
NOX4 expression in normal and SSc skin and in cultured normal and SSc dermal 
fibroblasts
To demonstrate and compare the NOX4 expression levels in cultured normal and SSc 
human dermal fibroblasts immunofluorescence studies were performed. The results showed 
that NOX4 was constitutively expressed by normal human dermal fibroblasts and that its 
expression was significantly higher in cultured SSc fibroblasts compared to cultured normal 
fibroblasts as illustrated for one representative experiment with one normal and one SSc cell 
line (Figure 1A). The increased NOX4 expression levels were confirmed by Western blot 
analysis of fibroblast cell extracts from cultured fibroblasts from three healthy donors and 
from four SSc patients. The results corroborated the increased levels of NOX4 protein in 
SSc dermal fibroblasts observed by immunofluorescence (Figure 1B, upper panel). ImageJ 
analysis of the Western blots following correction for the total amount of protein loaded into 
the gels (from comassie blue staining loading control) showed that on average NOX4 
protein levels measured in three different normal fibroblast lines compared to four different 
SSc fibroblast lines were greater than 3-fold higher in SSc fibroblasts (Figure 1B, lower 
panel). This difference was highly significant (p = 0.018).
Immunohistological detection of NOX4 epitopes was performed in skin biopsy samples 
from 3 normal controls and from 4 SSc patients with diffuse cutaneous SSc recent onset [41, 
42]. The results showed numerous fibroblastic cells displaying intense NOX4 staining in the 
samples of SSc skin (black arrows in Figure 1C) in contrast with negative staining in normal 
skin samples.
Stimulation of NOX4 expression by TGF-β1
To study the mechanisms responsible for the increased levels of NOX4 in SSc fibroblasts 
we examined whether TGF-β, the potent profibrotic growth factor generally accepted to play 
a crucial role in the pathogenesis of tissue fibrosis in SSc, was capable of stimulating NOX4 
expression. To evaluate this possibility we examined the effects of TGF-β on NOX4 
expression by cultured normal and SSc dermal fibroblasts. The results showed that TGF-β1 
induced a greater than 4-fold stimulation of NOX4 transcripts in normal dermal fibroblasts 
as shown in Figure 2A (upper panel). Although SSc fibroblasts displayed increased baseline 
levels of NOX4 transcripts compared to normal fibroblasts TGF-β treatment also induced a 
greater than two-fold increase in NOX4 mRNA levels in SSc fibroblasts as shown in Figure 
2A (lower panel).
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Regulation of NOX4 expression by PKC-δ
Because previous studies showed that PKC-δ was a crucial kinase involved in the expression 
of numerous fibrotic tissue components in SSc [42], we examined the effect of PKC-δ 
inhibition on TGF-β stimulated NOX4 transcript levels. The results showed that the 
stimulation of NOX4 gene expression induced by TGF-β was almost completely abrogated 
by the selective PKC-δ inhibitor rottlerin (Figure 2A). A similar pattern was found at the 
protein level assessed by Western blots for NOX4 (Figure 2B). However, owing to the 
controversy related to the specificity of rottlerin as an inhibitor of PKC-δ, an alternative 
study using small PKC-δ interfering RNA (siRNA) was performed in order to address these 
concerns. Normal dermal fibroblasts were transfected with either a negative control siRNA 
or with various combinations of specific siRNA directed against PKC-δ. RNA and cell 
extracts were isolated and Real Time PCR performed. PCR analysis showed a 50% 
reduction of PKC-δ mRNA expression using one of the siRNA combinations. The reduction 
of PKC-δ mRNA was accompanied by a similar reduction of NOX4 mRNA expression 
(Figure 2C). PKC-δ siRNA also caused a greater than 60% reduction in the potent 
stimulation of NOX4 induced by TGF-β as shown in Figure 2D.
Regulation of NOX4 expression by other kinases
To examine whether the canonical TGF-β intracellular pathway was involved in the 
stimulation of NOX4 by TGF-β, normal dermal fibroblasts were treated with TGF-β1 alone 
or in combination with either the cAbl specific inhibitor imatinib, or the Smad2/3 inhibitor, 
SB431542. Levels of NOX4 mRNA expression were determined by Real Time-PCR (Figure 
3A) and Western blots were performed to assess NOX4 protein levels in total cell protein 
extracts (Figure 3B). The results showed that imatinib caused only a 20–25% decrease in 
NOX4 mRNA expression and a 25–30% reduction in NOX4 protein levels whereas the 
Smad 2/3 inhibitor completely abrogated NOX4 mRNA expression in TGF-β1 treated 
fibroblasts (Figure 3A). The Smad2/3 inhibitor also reduced by greater than 50% the levels 
of NOX4 protein assessed by Western blots (Figure 3B).
Effects of stimulation or inhibition of NOX4 expression or activity on ROS production in 
normal dermal fibroblasts
To study the effects of NOX4 expression on ROS production by dermal fibroblasts the 
levels of ROS in live cultured cells were examined by analysis of fluorescence using 
carboxy-H2DCFDA. This compound permeates live cells and is deacetylated by nonspecific 
intracellular esterases. In the presence of ROS the reduced fluorescein compound is oxidized 
and emits bright fluorescence. In order to identify ROS specific production induced by 
NOX4, normal dermal fibroblasts were treated for 24 h with TGF-β1 to stimulate NOX4 
expression as described above, followed by incubation with GKT, the small molecule 
specific dual inhibitor of NOX4/NOX1. The results shown in Figure 4 demonstrate 
increased ROS production induced by TGF-β and a marked reduction of TGF-β stimulated 
ROS production by the specific NOX4/NOX1 inhibitor.
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Effects of inhibition of NOX4 activity on type I collagen and fibronectin expression in 
normal dermal fibroblasts
To assess whether inhibition of NOX4 activity resulted in changes in the expression of type 
I collagen and fibronectin we incubated normal dermal fibroblast cultures with increasing 
concentrations of GKT in the presence or absence of TGF-β1 to induce progressively greater 
inhibition of NOX4 activity and analyzed the effects on type I collagen and fibronectin 
transcript levels by real time PCR and on the production of type I collagen employing 
Western blots. The results (Figure 5) showed that GKT caused a dose-related reduction in 
type I collagen and fibronectin transcript levels both in unstimulated cultures and in cultures 
stimulated by TGF-β1 (Figure 5A), as well as a reduction in type I collagen protein 
production assessed by Western blots (Figure 5B).
Effect of NOX4 knockdown on ROS production and collagen type I production in SSc 
dermal fibroblasts
To directly examine whether NOX4 expression was involved in the increased production of 
Type I collagen in SSc cells SSc dermal fibroblasts were transfected with either a negative 
control siRNA or with various combinations of siRNA directed against NOX4. PCR 
analysis showed a 60% reduction of NOX4 mRNA expression using one of the siRNA 
combinations (Figure 6A). ROS production was notably reduced by siRNA NOX4 
knockdown as assessed by fluorescence measures (Figure 6B). Analysis of type I collagen 
protein levels secreted into the culture media showed that NOX4 siRNA caused a 20–30% 
reduction of collagen 1 protein levels depending of the SSc cell line studied (Figure 6C).
DISCUSSION
Several recent studies have suggested that oxidative stress is involved in SSc-associated 
fibrosis [18–23]. The mechanisms responsible for increased oxidative stress in SSc are a 
reduction of endogenous antioxidants and a parallel overproduction of ROS. ROS play both 
a deleterious and a beneficial dual role. Under physiological conditions ROS perform 
important functions in cellular signaling pathways as well as in host defense, however, in 
pathological states ROS can induce oxidative stress causing damage to proteins, lipids, and 
DNA, as well as activating various deleterious redox-sensitive pathways. Although ROS are 
produced by normal fibroblasts and are essential for numerous homeostatic intracellular 
functions, including regulation of cellular proliferation, there is evidence that SSc dermal 
fibroblasts produce increased ROS [18, 21, 44] and it has been suggested that elevated ROS 
levels may be involved in the increased collagen expression in these cells. The experiments 
described here showed increased levels of NOX4 epitopes in fibroblastic cells of skin 
biopsies from patients with diffuse cutaneous SSc of recent onset in comparison to samples 
of normal skin. In vitro studies employing cultures of normal and SSc dermal fibroblasts 
showed a marked increase in NOX4 expression and ROS production by SSc dermal 
fibroblasts in culture in comparison with normal dermal fibroblasts. Furthermore, it was 
shown that most of ROS are produced by NOX4 since inhibition of its activity by a highly 
selective NOX4 inhibitor or downregulation by specific NOX4 siRNA transfection caused a 
profound decrease in ROS levels. It should be emphasized, however, that because the small 
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molecule inhibitor we employed also inhibits NOX1 a role of NOX1 in regulation of ROS 
production cannot be completely excluded.
TGF-β signaling has been implicated as one of the most crucial mechanisms responsible for 
the fibrotic process in SSc pathogenesis [1–6,12–14]. In agreement with studies from other 
investigators [45–47] we found that TGF-β caused a potent stimulation of NOX4 expression 
in normal dermal fibroblasts as well as in SSc fibroblasts. Owing to the fact that NOX4 
lacks regulatory subunits and is generally accepted that the expression of NOX mRNA and 
the resulting protein levels determine the extent of its activity [31], these observations 
strongly implicate ROS as a participant in the SSc fibrotic process. We also investigated 
some of the canonical and non-canonical signaling pathways involved in TGF-β stimulation 
of NOX4. Among the non-canonical TGF-β pathways substantial interest has been recently 
focused on the PKC-δ and c-Abl kinase pathways [1,8,16,42]. Several studies have 
suggested a prominent role of PKC-δ in the pathogenesis of fibrotic diseases including SSc. 
Indeed, cultured dermal fibroblasts from SSc patients were shown to contain higher PKC-δ 
levels than normal cells and further studies demonstrated that PKC-δ was capable of 
inducing a potent stimulation of collagen gene expression [42]. The results described here 
indicate that PKC-δ mediated-pathways participate in the upregulation of NOX4 
transcription induced by TGF-β since PKC-δ inhibition employing rottlerin, a highly 
selective PKC-δ inhibitor, and PKC-δ knockdown employing siRNA abrogated or decreased 
TGF-β induction of NOX4 expression. Furthermore, Smad2/3 was also shown to be 
involved in this regulation since the specific Smad2/3 inhibitor SB431542 caused essentially 
complete abrogation of TGF-β1 stimulation of NOX4 expression. In contrast, inhibition of 
c-Abl with Imatinib caused only a minor reduction of 20–25% indicating that the c-Abl 
contribution to ROS production in SSc fibroblasts is minor and fail to support the existence 
of the mutually stimulatory interaction between c-Abl and PKC-δ in response to oxidative 
stress described previously [48]. Therefore, our results demonstrate that both canonical 
(Smad2/3) and non-canonical pathways (PKC-δ) pathways are implicated in the stimulation 
of NOX4 expression induced by TGF-β but that c-Abl does not appear to be involved. One 
important observation in these studies was that inhibition of NOX4 activity with the small 
molecule inhibition GKT caused a dose-related inhibitory effect in type I collagen and 
fibronectin transcript levels and a decrease in type I collagen protein levels in normal dermal 
fibroblasts. Of greater relevance to the pathogenesis of SSc were our observations that 
siRNA-induced knockdown of NOX4 expression resulted in a substantial reduction ROS 
production which was accompanied by a reduction in the levels of type I collagen produced 
by SSc fibroblasts providing strong support for the important pro-fibrogenic role of NOX4 
and as a downstream mediator of the TGF-β-induced cascade of pro-fibrotic reactions. 
Following submission of our paper a recent publication also demonstrated upregulation of 
NOX4 expression in SSc fibroblasts and showed that treatment of the cells with a non-
selective NOX inhibitor or silencing of NOX4 with siRNA decreased type I collagen and α-
SMA expression in these cells [49]. Thus, the results from the studies described here 
together with those described by Spadoni et al. [49] collectively suggest an important role of 
this constitutively expressed NADPH oxidase in the pathogenesis of tissue fibrosis in SSc 
and in the regulation of TGF-β-induced pro-fibrotic molecular pathways. These results 
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further suggest that targeting the downstream TGF-β pathway by inhibiting NOX4 may 
represent a potentially effective anti-fibrotic therapy for this currently incurable disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A. Immunofluorescence analysis of NOX4 protein levels in cultured normal and SSc dermal 
fibroblasts. Representative NOX4 immunofluorescence in confluent cultures of one normal 
and one SSc dermal fibroblast cell line.
B. Western blot analysis of equal amounts of cell extracts from three normal and three SSc 
dermal fibroblasts probed with a specific NOX4 antibody (upper panel). The middle panel 
shows the same gel stained with comassie blue which was used as loading control for 
protein concentrations (middle panel). The bar graph (lower panel) represents the average 
NOX4 protein levels from 3 normal and 4 SSc cultured dermal fibroblast cell lines corrected 
for protein loading.* p value = 0.018. AU= arbitrary units of fluorescence.
C. Immunohistological staining of normal and SSc skin tissues for NOX4 epitopes. The 
images shown are representative of images obtained from 3 samples of normal skin and 4 
samples of affected SSc skin. Note intensely-stained NOX4 epitopes in numerous 
fibroblastic cells (black arrows) present only in SSc tissues (Magnification 10×). The insets 
show greater magnification images (Magnification 40×) of NOX4-positive cells in the SSc 
skin samples.
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Figure 2. 
A. NOX4 mRNA expression levels assessed in triplicate by Real Time PCR analysis in four 
normal dermal fibroblast cell lines under treatment with TGF-β1 and rottlerin. GAPDH was 
used as endogenous control. Lower panel shows the effect of TGF-β1 and rottlerin on three 
SSc cell lines.
B. Representative Western blot analysis of NOX4 and β-actin (as protein control) using cell 
extracts from four normal dermal fibroblast cell lines treated with TGF-β1 alone or TGF-β1 
plus rottlerin. Bar graph represents NOX4 protein levels following correction for the 
intensity of the β actin band.
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C. Bar graphs of PKC-δ and NOX4 mRNA expression by normal dermal fibroblasts 
following treatment with specific siRNA against PKC-δ. The data shown are the average of 
the siRNA effect on three normal dermal fibroblast cell lines.
D. Bar graph of PKC-δ expression by normal dermal fibroblasts following treatment with 
TGF-β1 and a specific siRNA against PKC-δ. The data shown are the average of duplicate 
experiments examining the PKC-δ siRNA effect on two normal dermal fibroblast cell lines.
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Figure 3. 
Real Time PCR analysis of NOX4 expression (A) and protein levels of NOX4 (B) by 
normal dermal fibroblasts under treatment with either TGF-β1 alone or with TGF-β1 plus 
either imatinib mesylate (Imat; cAbl inhibitor) or SB4315421 (SB43; Smad2/3 specific 
inhibitor). The results are the average of three separate experiments with three different cell 
lines. * p value < 0.05. A representative Western blot is shown in the inset.
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Figure 4. 
Fluorescence microscopy images of ROS levels in normal dermal fibroblasts treated with 
either TGF-β1 alone or TGF-β1 plus the NOX4/NOX1 small molecule inhibitor 
GKT137831 (GKT). The bar graph (lower panel) represents corrected total cell fluorescence 
(CTCF) of relative ROS production of TGF-β1 or TGF-β1 plus GKT inhibitor vs untreated 
cells in four separate experiments with two normal dermal fibroblast cell lines.* p value = 
0.005, ** p value = 0.02.
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Figure 5. 
A. Real Time PCR analysis of COL1A1 and FN1 expression by normal dermal fibroblasts 
treated with increasing concentration of the NOX4/NOX1 specific inhibitor GKT137831 
(GKT) and either culture media alone or culture media containing TGF-β1. The data shown 
are the average of the results obtained in three separate experiments performed with a 
normal cell line.
B. Representative image of a Western blot analysis for secreted collagen Type I from normal 
dermal fibroblasts treated with 10 µM GKT. The bar graph shows the average results 
obtained with four different cell lines.
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Figure 6. 
A. Bar graphs of NOX4 mRNA expression by SSc dermal fibroblasts following treatment 
with specific siRNA against NOX4. The data shown are the average of the siRNA effect on 
four SSc dermal fibroblast cell lines * p value < 0.05.
B. Fluorescence microscopy images and quantification of ROS levels in SSc dermal 
fibroblasts following treatment with specific siRNA against NOX4. The graph represents the 
average intensity of fluorescence (CTCF) of two SSc dermal fibroblast cell lines examined 
in duplicate * p value < 0.05.
C. Western blot analysis of secreted collagen Type I from the culture media of SSc dermal 
fibroblasts following NOX4 siRNA knockdown. Control cells were transfected with a 
scrambled inactive siRNA. The bar graph shows the average of results obtained with three 
separate SSc dermal fibroblast cell lines * p value < 0.01.
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